{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=LYMPHOCYTIC+LEUKEMIA+%28CLL%29+OR+SMALL+LYMPHOCYTIC+LYMPHOMA+%28SLL%29&page=55", "query": { "condition": "LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)", "page": 55 }, "page_size": 10 }, "pagination": { "page": 55, "page_size": 10, "total_count": 1562, "total_pages": 157, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=LYMPHOCYTIC+LEUKEMIA+%28CLL%29+OR+SMALL+LYMPHOCYTIC+LYMPHOMA+%28SLL%29&page=56&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=LYMPHOCYTIC+LEUKEMIA+%28CLL%29+OR+SMALL+LYMPHOCYTIC+LYMPHOMA+%28SLL%29&page=54&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-24T06:44:55.538Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06073821", "title": "Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "CLL" ], "interventions": [ { "name": "Sonrotoclax", "type": "DRUG" }, { "name": "Zanubrutinib", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Obinutuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeOne Medicines", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 652, "start_date": "2023-11-11", "completion_date": "2032-12", "has_results": false, "last_update_posted_date": "2026-10-14", "last_synced_at": "2026-10-24T06:44:55.538Z", "location_count": 40, "location_summary": "Anchorage, Alaska • Duarte, California • La Jolla, California + 35 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06073821" }, { "nct_id": "NCT07424833", "title": "A Study of APG-3288 in Relapsed/Refractory Blood Cancers", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapsed/Refractory Hematological Malignancies", "Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia (CLL/SLL", "Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL; Including Richter Transformation)", "Relapsed/Refractory Mantle Cell Lymphoma (MCL)", "Relapsed/Refractory Waldenström Macroglobulinemia (WM)", "Relapsed/Refractory Marginal Zone Lymphoma (MZL)", "Relapsed/Refractory Follicular Lymphoma (FL)" ], "interventions": [ { "name": "APG-3288", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ascentage Pharma Group Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 180, "start_date": "2026-03-10", "completion_date": "2031-12", "has_results": false, "last_update_posted_date": "2026-10-15", "last_synced_at": "2026-10-24T06:44:55.538Z", "location_count": 5, "location_summary": "Los Angeles, California • Jacksonville, Florida • Grand Rapids, Michigan + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "East Brunswick", "state": "New Jersey" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07424833" }, { "nct_id": "NCT00085449", "title": "Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Neoplasms" ], "interventions": [ { "name": "alemtuzumab", "type": "BIOLOGICAL" }, { "name": "cyclosporine", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" }, { "name": "mycophenolate mofetil", "type": "DRUG" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 0, "start_date": "2006-05", "completion_date": "2007-01", "has_results": false, "last_update_posted_date": "2019-11-27", "last_synced_at": "2026-10-24T06:44:55.538Z", "location_count": 24, "location_summary": "La Jolla, California • Los Angeles, California • San Francisco, California + 19 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Newark", "state": "Delaware" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00085449" }, { "nct_id": "NCT00410163", "title": "Ofatumumab With Fludarabine and Cyclophosphamide in B-CLL Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukaemia, Lymphocytic, Chronic" ], "interventions": [ { "name": "Ofatumumab 500mg", "type": "DRUG" }, { "name": "Ofatumumab 1000mg", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 61, "start_date": "2007-01", "completion_date": "2013-05", "has_results": true, "last_update_posted_date": "2014-02-10", "last_synced_at": "2026-10-24T06:44:55.538Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00410163" }, { "nct_id": "NCT01209130", "title": "A Study of the Safety and Pharmacokinetics of Escalating Doses of DCDT2980S in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia And DCDT2980S in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia" ], "interventions": [ { "name": "DCDT2980S", "type": "DRUG" }, { "name": "rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 91, "start_date": "2010-10", "completion_date": "2015-03", "has_results": false, "last_update_posted_date": "2016-11-02", "last_synced_at": "2026-10-24T06:44:55.538Z", "location_count": 9, "location_summary": "Stanford, California • Denver, Colorado • Washington D.C., District of Columbia + 5 more", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01209130" }, { "nct_id": "NCT04215809", "title": "Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "CLL/SLL" ], "interventions": [ { "name": "Lisaftoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ascentage Pharma Group Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 144, "start_date": "2020-03-02", "completion_date": "2027-06-30", "has_results": false, "last_update_posted_date": "2025-04-10", "last_synced_at": "2026-10-24T06:44:55.538Z", "location_count": 7, "location_summary": "Duarte, California • Jacksonville, Florida • Boston, Massachusetts + 4 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Canton", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04215809" }, { "nct_id": "NCT01652014", "title": "Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Accelerated Phase Chronic Myelogenous Leukemia", "Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome", "Adult Acute Lymphoblastic Leukemia in Remission", "Adult Acute Myeloid Leukemia in Remission", "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Adult Nasal Type Extranodal NK/T-cell Lymphoma", "Anaplastic Large Cell Lymphoma", "Angioimmunoblastic T-cell Lymphoma", "Blastic Phase Chronic Myelogenous Leukemia", "Cutaneous B-cell Non-Hodgkin Lymphoma", "de Novo Myelodysplastic Syndromes", "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "Hepatosplenic T-cell Lymphoma", "Intraocular Lymphoma", "Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable", "Nodal Marginal Zone B-cell Lymphoma", "Noncutaneous Extranodal Lymphoma", "Peripheral T-cell Lymphoma", "Post-transplant Lymphoproliferative Disorder", "Previously Treated Myelodysplastic Syndromes", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Myeloid Leukemia", "Recurrent Adult Burkitt Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Diffuse Mixed Cell Lymphoma", "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma", "Recurrent Adult Grade III Lymphomatoid Granulomatosis", "Recurrent Adult Hodgkin Lymphoma", "Recurrent Adult Immunoblastic Large Cell Lymphoma", "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent Adult T-cell Leukemia/Lymphoma", "Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Mycosis Fungoides/Sezary Syndrome", "Recurrent Small Lymphocytic Lymphoma", "Refractory Chronic Lymphocytic Leukemia", "Refractory Hairy Cell Leukemia", "Refractory Multiple Myeloma", "Relapsing Chronic Myelogenous Leukemia", "Secondary Acute Myeloid Leukemia", "Secondary Myelodysplastic Syndromes", "Small Intestine Lymphoma", "Splenic Marginal Zone Lymphoma", "T-cell Large Granular Lymphocyte Leukemia", "Testicular Lymphoma", "Waldenström Macroglobulinemia" ], "interventions": [ { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "mycophenolate mofetil", "type": "DRUG" }, { "name": "allogeneic hematopoietic stem cell transplantation", "type": "PROCEDURE" }, { "name": "umbilical cord blood transplantation", "type": "PROCEDURE" }, { "name": "double-unit umbilical cord blood transplantation", "type": "PROCEDURE" }, { "name": "total-body irradiation", "type": "RADIATION" }, { "name": "tacrolimus", "type": "DRUG" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "University of Medicine and Dentistry of New Jersey", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 0, "start_date": "2014-01", "completion_date": "2017-01", "has_results": false, "last_update_posted_date": "2016-07-14", "last_synced_at": "2026-10-24T06:44:55.538Z", "location_count": 1, "location_summary": "New Brunswick, New Jersey", "locations": [ { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT01652014" }, { "nct_id": "NCT05281809", "title": "Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "B-Cell Lymphoma", "B Acute Lymphoblastic Leukemia", "Diffuse Large B Cell Lymphoma", "Mantle Cell Lymphoma", "Follicular Lymphoma", "Marginal Zone Lymphoma", "Lymphoplasmacytic Lymphoma", "Chronic Lymphocytic Leukemia", "Transformed Lymphoma" ], "interventions": [ { "name": "Chimeric Antigen Receptor (CAR) T-Cell Product (Autologous)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "John Lister", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "79 Years", "sex": "ALL", "summary": "18 Years to 79 Years" }, "enrollment_count": 30, "start_date": "2022-04-19", "completion_date": "2037-12-01", "has_results": false, "last_update_posted_date": "2025-01-13", "last_synced_at": "2026-10-24T06:44:55.538Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05281809" }, { "nct_id": "NCT00003406", "title": "Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Refractory Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Chronic Myeloproliferative Disorders", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Precancerous/Nonmalignant Condition", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "carboplatin", "type": "DRUG" }, { "name": "docetaxel", "type": "DRUG" }, { "name": "ifosfamide", "type": "DRUG" }, { "name": "autologous bone marrow transplantation", "type": "PROCEDURE" }, { "name": "bone marrow ablation with stem cell support", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Cancer Treatment Centers of America", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "65 Years", "sex": "ALL", "summary": "Up to 65 Years" }, "enrollment_count": 30, "start_date": "1997-10", "completion_date": "2000-03", "has_results": false, "last_update_posted_date": "2013-03-26", "last_synced_at": "2026-10-24T06:44:55.538Z", "location_count": 1, "location_summary": "Zion, Illinois", "locations": [ { "city": "Zion", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003406" }, { "nct_id": "NCT02677948", "title": "Multicenter Study of Pacritinib Combined With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Chronic Lymphocytic Leukemia", "Lymphoma, Small Lymphocytic" ], "interventions": [ { "name": "Pacritinib", "type": "DRUG" }, { "name": "Ibrutinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Michigan Rogel Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "79 Years", "sex": "ALL", "summary": "18 Years to 79 Years" }, "enrollment_count": 0, "start_date": "2016-10", "completion_date": "2018-10", "has_results": false, "last_update_posted_date": "2017-09-06", "last_synced_at": "2026-10-24T06:44:55.538Z", "location_count": 2, "location_summary": "Ann Arbor, Michigan • Rochester, Minnesota", "locations": [ { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02677948" } ] }